EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC 4.0

Effects of a Protease Inhibitor Camostat Mesilate on Gut Microbial Function in Patients with Irritable Bowel Syndrome: A Pilot Randomized Placebo-Controlled Study

Motoyori Kanazawa, Kentaro Miyamoto, Michiko Kano, Kyoko Inooka, Kentaro Oka, Motomichi Takahashi, Nariyasu Mano, Shin Fukudo

Digestion · 2024

DOI: 10.1159/000542758 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Digestion, 2024. Verfasst von Motoyori Kanazawa und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Behavioral Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan. Hauptthemen laut MEDLINE: Gastrointestinal Microbiome, Irritable Bowel Syndrome, Guanidines, Gabexate. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Increased fecal protease activity, which may induce visceral hypersensitivity, has been observed in patients with irritable bowel syndrome (IBS). Serine proteases modulate FK506 binding protein (FKBP)-type peptidylprolyl cis-trans isomerase (PPIase) activity associated with immune and glucocorticoid receptor functions. The aim was to investigate whether camostat mesilate (CM), a serine protease inhibitor, modifies fecal bacterial function related to FKBP-type PPIases in patients with IBS.

Methods

Randomly assigned 16 patients with IBS received 200 mg po tid of CM and 16 patients received placebo for 14 days. Self-reported adequate relief (AR) as a primary endpoint, IBS Symptom Severity Scale (IBS-SSS), and colonic motor and pain thresholds to colorectal distention were assessed before and after treatment. The fecal bacterial content was inferred from 16S rRNA gene sequence data using Phylogenetic Investigation of Communities by Reconstruction of Unobserved States and the Kyoto Encyclopedia of Genes and Genomes database.

Results

CM significantly increased the relative abundance of Streptococcus and the functional abundances of serine protease and FKBP-type PPIase FkpA, FklB and SlyD more than placebo after treatment. CM treatment was not superior to placebo in proportion of AR although colonic motor response partially changed.

Conclusion

CM modulated the fecal microbiome composition and functional potentials that are related to FKBP-type PPIase activity in IBS patients. These findings suggest that protease inhibitors may modify gut microbial function along with abnormal immunological and/or stress responses that underlie pathophysiology of IBS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Gastrointestinal MicrobiomeIrritable Bowel SyndromeGuanidinesGabexateSerine Proteinase InhibitorsHumansMaleFemaleFecesPilot ProjectsAdultMiddle AgedTreatment OutcomeDouble-Blind MethodSeverity of Illness IndexBacteriaRNA, Ribosomal, 16SEsters

Stichwörter der Autor:innen

Irritable bowel syndromeMicrofloraProtease inhibitor

Substanzen

GuanidinescamostatGabexateSerine Proteinase InhibitorsRNA, Ribosomal, 16SEsters

Autor:innen und Institutionen

  • Department of Behavioral Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.
  • R and D Division, Central Research Institute, Miyarisan Pharmaceutical Co., Ltd., Saitama, Japan.
  • Department of Pharmacy, Miyagi Cancer Center, Natori, Japan.
  • Department of Pharmaceutical Sciences, Tohoku University Hospital, Sendai, Japan.

Zitieren

APA

Kanazawa, M., Miyamoto, K., Kano, M., Inooka, K., Oka, K., Takahashi, M., Mano, N., & Fukudo, S. (2024). Effects of a Protease Inhibitor Camostat Mesilate on Gut Microbial Function in Patients with Irritable Bowel Syndrome: A Pilot Randomized Placebo-Controlled Study. Digestion. https://doi.org/10.1159/000542758

Vancouver

Kanazawa M, Miyamoto K, Kano M, Inooka K, Oka K, Takahashi M, et al. Effects of a Protease Inhibitor Camostat Mesilate on Gut Microbial Function in Patients with Irritable Bowel Syndrome: A Pilot Randomized Placebo-Controlled Study. Digestion. 2024. doi:10.1159/000542758

BibTeX
@article{Kanazawa2024,
  author = {Kanazawa, Motoyori and Miyamoto, Kentaro and Kano, Michiko and Inooka, Kyoko and Oka, Kentaro and Takahashi, Motomichi and Mano, Nariyasu and Fukudo, Shin},
  title = {Effects of a Protease Inhibitor Camostat Mesilate on Gut Microbial Function in Patients with Irritable Bowel Syndrome: A Pilot Randomized Placebo-Controlled Study},
  journal = {Digestion},
  year = {2024},
  doi = {10.1159/000542758}
}
Kostenlos starten →